巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Comera Life Sciences Holdings

    CMRA
    1.800
    0.130
    7.78%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Comera Life Sciences Holdings - 延遲價格・最後更新於 23/09 12:00
    最高位
    1.830
    最低位
    1.610
    開市價
    --
    前收市價
    1.670
    成交量(千)
    7.53
    成交額(百萬)
    0.11
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    34.36
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    15.300 - 1.110
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Comera Life Sciences Holdings
    證券代碼
    CMRA.US
    所屬板塊
    Biotechnology
    公司業務
    Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting a formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera’s internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company’s partners’ biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
    發行量
    19087185
    公司總部
    12 Gill Street, Suite 4650
    公司網址
    https://www.comeralifesciences.com
    公司電話
    +1 617 871-2101
    暫無內容

    關於

    Comera Life Sciences Holdings(CMRA.US)所屬的行業板塊為Biotechnology。
    Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting a formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera’s internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company’s partners’ biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
    詳細公司背景可參考: https://www.comeralifesciences.com